



2003-06-26

CMA Microdialysis AB announces the release of its new High Cut-Off Membrane Catheter.

CMA Microdialysis AB today announced that it has received CE Marking and will release its new CMA71 High Cut-Off Brain Microdialysis Catheter.

The catheter will allow intensivists, surgeons to sample large molecules such as cytokines that was not previously possible with the existing brain catheters. Cytokines are seen as clear early markers of inflammation.

“The release of this unique product opens up a completely new opportunity for physicians to conveniently measure inflammatory substances and we are confident that it will help in improving monitoring in critical care e.g. in septic patients ” says Mark Dumenil, Chief Executive Officer of CMA Microdialysis AB

This is another milestone in the history of the company as it widens its focus in critical care medicine.

About CMA

CMA Microdialysis is the leading company devoted to the development, manufacturing and marketing of the Microdialysis technique. The company was formed in 1984 and was the first company in the world to market Microdialysis products and know-how. Consumables, instruments and computer software are sold to universities, hospitals and pharmaceutical companies as unique tools for *in vivo* sampling of organs and tissues. CMA has offices in Sweden, USA and Germany and a total of 60 employees